Confusion regarding duration of insulin action: A potential source for major insulin dose errors by bolus calculators

Journal of Diabetes Science and Technology

Volumn 8, Issue 1, 2014, Pages 170-178

  Walsh, John ^a   Roberts, Ruth ^b   Heinemann, Lutz ^c  

^a Advanced Metabolic Care + Research   (United States)

^b Diabetes Services Inc   (United States)

^c Science and Co   (Germany)

Author keywords

Duration of insulin action; Insulin action time; Insulin pumps; Insulin therapy; Pharmacodynamics; Pharmacokinetics; Rapid acting insulin analogs

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

CALCULATOR; CONFUSION; DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; NONHUMAN; NOTE; PHARMACODYNAMICS;

EID: 84900539961     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813514319     Document Type: Note

References (31)

1. Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28(3):533-538.
2. Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol. 2010;4:1174-1181.
3. Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care. 2000;23:1232-1235.
4. Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol. 2011;5:1711-1717.
5. Heinemann L. Time-Action Profiles of Insulin Preparations. Mainz, Germany: Kirchchem & C. GmbH; 2004.
6. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapidacting insulin analog insulin aspart. Diabetes Care. 1998;21(11):1910-1914.
7. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther. 2009;11(6):345-352.
8. Steiner S, Hompesch M, Pohl R, et al. A novel insulin formulation with a more rapid onset of action. Diabetologia. 2008;51(9):1602-1606.
9. Rave KM, Nosek L, de la Peña A, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care. 2005;28(10):2400-2405.
10. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28(5):1077-1082.
11. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501-1506.
12. Walsh J, Wroblewski D, Bailey TS. Disparate bolus recommendations in insulin pump therapy. Poster presented at: American Association of Clinical Endocrinology; 2007. Available at: http://www.diabetesnet.com/pdfs/ AACE2007Poster.pdf.
13. O'Connell MA, Donath S, Cameron SJ. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes. 2011;12(6):556-559.
14. Zisser H, Robinson L, Bevier W, et al. Bolus calculator: a review of four "smart" insulin pumps. Diabetes Technol Ther. 2008;10(6):441-444.
15. NovoLog product handout; 2002-2011. Available at: http://www.novo-pi.com/ novolog.pdf.
16. Heinemann L, Anderson JH Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004;6:698-718.
17. Becker RH, Frick AD, Nosek L, Heinemann L, Rave K. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care. 2007;30:2506-2507.
18. Walsh J. Proposed insulin pump standards; 2008. Available at: http://www.diabetesnet.com/diabetes-presentations/proposedinsulinpumpstandards. html.
19. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4:673-682.
20. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
21. Elahi D, Meneilly GS, Minaker KL, Andersen DK, Rowe JW. Escape of hepatic glucose production during hyperglycemic clamp. Am J Physiol. 1989;257:E704-E711.
22. http://www.tudiabetes.org/forum/topics/duration-of-insulin-action-on.
23. Buckingham BA, Block J, Wilson D, Rebrin K, Steil G. NovoLog pharmacodynamics in toddlers. Diabetes. 2005;54(suppl 1):1889-P.
24. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr. 2000;159(7);483-488.
25. Apidra product monograph. Version 10. 2012. Available at: http://products.sanofi.ca/en/apidra.pdf.
26. Ford Heritage. Composition and Facts About Foods. Pomeroy, WA: Health Research Books; 1996.
27. Heinemann L, Steiner S. Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same? J Diabetes Sci Technol. 2011;5:1027-1029.
28. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728-742.
29. Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem. January 2004;50(1);257-259.
30. Walsh J, Roberts R. Pumping Insulin. 5.1 ed. San Diego, CA: Torrey Pines Press; 2013.
31. Heise T, Heinemann L, Hövelmann U, et al. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and basal-bolus therapy. Diabetes Care. 2009;32:1431-1433.